Clinical trials: Pemphigus
Pemphigus, Pemphigus Vulgaris
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
- Conditions
- Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus
- Trial name
- NCT03075904
- Testing
- ALXN1830
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Oral Pemphigus Vulgaris
Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris
Comparing the effect of injecting autologous platelet rich plasma and triamcinolone acetonide in the erosions of buccal mucosa of pemphigus vulgaris patients.
- Trial name
- NCT02828163
- Testing
- Autologous Platelet rich plasma, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 11 people
- Sponsor
- Cairo University
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC
Pemphigus, Auto-immune Thrombocytopenic Purpura
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.
- Conditions
- Pemphigus, Auto-immune Thrombocytopenic Purpura, Hemolytic Auto-immune Anaemia, Cold Agglutinin Disease
- Trial name
- RITAI (NCT00960713)
- Testing
- Rituximab (MABTHERA® or RITUXAN®).
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Pemphigus Vulgaris
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.
- Trial name
- NCT00063752
- Testing
- PI-0824
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Peptimmune
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Pemphigus Foliaceus, Pemphigus Vulgaris
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
T cells, a type of white blood cell called a lymphocyte, play an important role in the immune system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may provide protection against the…
- Trial name
- NCT03239470
- Testing
- Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Pemphigus
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients.
- Trial name
- NCT01338103
- Testing
- Rituximab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Disasters, Disaster Preparedness
Effectiveness of an Audiovisual Disaster-Education Intervention on Disaster Risk Perception and Preparedness Belief Among Senior High-School Adolescents
This cluster-randomized controlled trial tests whether a short, standardized disaster-education video improves two psychological precursors of disaster preparedness among senior high-school students in a hazard-prone district of…
- Conditions
- Disasters, Disaster Preparedness, Health Behavior, Risk Perception
- Trial name
- DERAP (NCT07781527)
- Testing
- Audiovisual disaster-education module, Attention-matched general-health video
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Tanjungpura University
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Galectin-3 and Pemphigus
Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients
Assessment of the expression of galectin-3 in serum and saliva of pemphigus patients and compare it with age and sex matched controls.
- Trial name
- NCT05992727
- Testing
- Galectin 3 measurement in serum and saliva by ELIZA
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active…
- Trial name
- NCT04422912
- Testing
- DSG3-CAART, CABA-201
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cabaletta Bio
Pemphigus Vulgaris
Use of KC706 for the Treatment of Pemphigus Vulgaris
The purpose of this study is to determine whether KC706 is effective in the prevention and healing of blisters in patients with pemphigus vulgaris, while the patient remains on stable doses of corticosteroids and/or…
- Trial name
- NCT00606749
- Testing
- KC706
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kemia, Inc
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
The proposed study is an open-label, non-controlled, adaptive-design Phase II study to evaluate the safety, pharmacodynamics, pharmacokinetics, efficacy, and conditions of use (dosage, frequency of administration at maintenance)…
- Trial name
- NCT03334058
- Testing
- ARGX-113
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 34 people
- Sponsor
- argenx
Pemphigus
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
- Trial name
- NCT00010413
- Testing
- cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Johns Hopkins University
Pemphigus Vulgaris (PV), Periodontal Diseases
Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients
The aim of this study is to evaluate the relationship between the severity of Pemphigus Vulgaris (a chronic autoimmune skin disease) and periodontal (gum) health, and to compare the findings with those of a systemically healthy…
- Trial name
- NCT07384221
- Testing
- Clinical Periodontal and Oral Evaluation
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Pemphigus Vulgaris
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.
- Trial name
- NCT01920477
- Testing
- Ofatumumab
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Pemphigus
Coagulation Activation in Patients With Pemphigus
Aim of work: 1. To evaluate the plasma markers of coagulation activation: prothrombin F1+2 and d-dimer levels in pemphigus patients with active disease and compare them with age and sex-matched controls. 2.
- Trial name
- NCT06285435
- Testing
- prothrombin fragment 1+2
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Assiut University